Kawakami et al. observed that gastric cancer treatment with 5FU leads to enrichment of residual cells overexpressing aldehyde dehydrogenase 1A3 (ALDH1A3), which was identified as a key survival factor of drug-tolerant persister cells in gastric cancer [64]. Here, ALDH1A3 is linked to gastric cancer.